An Injectable Hydrogel Releasing Drug-Laden Micelle <em>in situ</em> for Anticancer Immunotherapy
발표자
()
초록
내용
Tumor-draining lymph nodes (TdLNs) and tumor microenvironments orchestrate differentiations and functions of CD8 T cells. Herein, three different approaches to exploit an injectable hydrogel (F127-g-Gelatin) in efficient immunotherapy are introduced. First, F127-g-Gelatin hydrogel was introduced for the efficient memory CD8 T cell modulations in the tumor microenvironments in the codelivery of BRAF inhibitor and immune checkpoint blockades. In the second project, an approach using the hydrogel to deliver CpG oligonucleotides into TdLNs in a sustained manner was discussed to invigorate therapeutic effects of immune checkpoint blockades. Third, the hydrogel was revealed to release in situ drug-laden micelles with appropriate size for lymphatic delivery, which elicited successful immunotherapy in the co-delivery of aCTLA-4 antagonistic and nitric oxide. This F127-g-Gelatin can represent a platform for efficient and prolonged immunotherapy focusing on TdLNs and tumor microenvironment.